PL2496568T3 - Związek polimorficzny 3-(podstawionej dihydroizoindolinon-2-ylo)-2,6- dioksopiperydyny i jego kompozycje farmaceutyczne - Google Patents

Związek polimorficzny 3-(podstawionej dihydroizoindolinon-2-ylo)-2,6- dioksopiperydyny i jego kompozycje farmaceutyczne

Info

Publication number
PL2496568T3
PL2496568T3 PL10825954T PL10825954T PL2496568T3 PL 2496568 T3 PL2496568 T3 PL 2496568T3 PL 10825954 T PL10825954 T PL 10825954T PL 10825954 T PL10825954 T PL 10825954T PL 2496568 T3 PL2496568 T3 PL 2496568T3
Authority
PL
Poland
Prior art keywords
substituteddihydroisoindolinone
dioxopiperidine
polymorph
pharmaceutical compositions
pharmaceutical
Prior art date
Application number
PL10825954T
Other languages
English (en)
Inventor
Rong Yan
Hao Yang
Yongxiang Xu
Original Assignee
Nanjing Cavendish Bio-Engineering Technology Co., Ltd.
Rong Yan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Cavendish Bio-Engineering Technology Co., Ltd., Rong Yan filed Critical Nanjing Cavendish Bio-Engineering Technology Co., Ltd.
Publication of PL2496568T3 publication Critical patent/PL2496568T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL10825954T 2009-11-02 2010-11-02 Związek polimorficzny 3-(podstawionej dihydroizoindolinon-2-ylo)-2,6- dioksopiperydyny i jego kompozycje farmaceutyczne PL2496568T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2009102103923A CN101696205B (zh) 2009-11-02 2009-11-02 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
PCT/CN2010/001751 WO2011050590A1 (en) 2009-11-02 2010-11-02 Polymorph of 3-(substituteddihydroisoindolinone-2-yl)-2,6-dioxopiperidine, and pharmaceutical compositions thereof
EP10825954.0A EP2496568B1 (en) 2009-11-02 2010-11-02 Polymorph of 3-(substituteddihydroisoindolinone-2-yl)-2,6-dioxopiperidine, and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
PL2496568T3 true PL2496568T3 (pl) 2017-12-29

Family

ID=42141345

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10825954T PL2496568T3 (pl) 2009-11-02 2010-11-02 Związek polimorficzny 3-(podstawionej dihydroizoindolinon-2-ylo)-2,6- dioksopiperydyny i jego kompozycje farmaceutyczne

Country Status (9)

Country Link
US (1) US9101620B2 (pl)
EP (1) EP2496568B1 (pl)
JP (1) JP2013509357A (pl)
KR (1) KR20130026414A (pl)
CN (1) CN101696205B (pl)
AU (1) AU2010312224B2 (pl)
ES (1) ES2634666T3 (pl)
PL (1) PL2496568T3 (pl)
WO (1) WO2011050590A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
CN101696205B (zh) 2009-11-02 2011-10-19 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
CN104072476B (zh) * 2013-03-27 2018-08-21 江苏豪森药业集团有限公司 泊马度胺晶型及其制备方法和用途
CN104016966A (zh) * 2014-01-30 2014-09-03 上海创诺制药有限公司 3-(4-氨基-1,3-二氢-1-氧代-2h-异吲哚-2-基)-2,6-哌啶二酮新晶型及其制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2177517E (pt) 1996-07-24 2011-11-10 Celgene Corp 2-(2,6-dioxopiperidin-3-il)-ftalimida amino-substituída para redução dos níveis de tnf-alfa
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
AU2003237078C1 (en) 2002-04-12 2009-10-08 Celgene Corporation Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
EP2272513A1 (en) 2002-05-17 2011-01-12 Celgene Corporation Pharmaceutical compositions for treating cancer
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20050203142A1 (en) 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
ZA200503240B (en) 2002-10-24 2007-11-28 Gelgene Corp Methods of using and compositions comprising immunodulatory compounds for treatment, modification and management of pain
US20040091455A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
MXPA05004488A (es) 2002-10-31 2005-07-26 Celgene Corp Composicion para el tratamiento de la degeneracion macular.
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
UA89474C2 (uk) 2003-05-15 2010-02-10 Селджин Корпорейшн Способи і композиції з використанням імуномодулюючих сполук для лікування і підтримки стану при раку і інших захворюваннях
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20050100529A1 (en) 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
NZ548049A (en) 2003-12-02 2009-01-31 Celgene Corp Methods and compositions for the treatment and management of hemoglobinopathy and anemia
US20050143344A1 (en) 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
MXPA06010699A (es) 2004-03-22 2006-12-15 Celgene Corp Metodos de usos y composiciones que contienen compuestos inmunomoduladores para el tratamiento y manejo de enfermedades o alteraciones de la piel.
US20050222209A1 (en) 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
CN1968695A (zh) 2004-04-14 2007-05-23 细胞基因公司 含有用于治疗和控制骨髓发育不良综合征的免疫调节化合物的组合物和使用方法
JP2007533761A (ja) 2004-04-23 2007-11-22 セルジーン・コーポレーション 肺高血圧症を治療し管理するための、免疫調節性化合物の使用方法及び免疫調節性化合物を含む組成物
WO2005112928A1 (en) 2004-05-05 2005-12-01 Celgene Corporation Method of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
ES2437592T3 (es) 2004-09-03 2014-01-13 Celgene Corporation Procedimientos para la preparación de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
ZA200704784B (en) 2004-11-12 2008-10-29 Celgene Corp Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases
CA2588597A1 (en) 2004-11-23 2006-06-01 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
CN101111234A (zh) 2004-12-01 2008-01-23 细胞基因公司 包含免疫调节化合物的组合物及其治疗免疫缺陷疾病的用途
WO2009111948A1 (zh) 2008-03-13 2009-09-17 天津和美生物技术有限公司 3-(4-氨基-1-氧代-1,3-二氢异吲哚-2-基)哌啶-2,6-二酮及其衍生物的盐或盐的多晶型物及其制备和应用
TWI475014B (zh) * 2009-09-17 2015-03-01 Scinopharm Taiwan Ltd 固體形態的３－（４－胺基－１－側氧基－１，３－二氫－異吲哚－２－基）－哌啶－２，６－二酮及其製造方法
CN101696205B (zh) 2009-11-02 2011-10-19 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物

Also Published As

Publication number Publication date
US20120203005A1 (en) 2012-08-09
WO2011050590A1 (en) 2011-05-05
JP2013509357A (ja) 2013-03-14
AU2010312224A1 (en) 2012-04-12
AU2010312224B2 (en) 2014-04-10
CN101696205A (zh) 2010-04-21
EP2496568A4 (en) 2013-04-24
EP2496568B1 (en) 2017-04-26
KR20130026414A (ko) 2013-03-13
CN101696205B (zh) 2011-10-19
US9101620B2 (en) 2015-08-11
ES2634666T3 (es) 2017-09-28
EP2496568A1 (en) 2012-09-12

Similar Documents

Publication Publication Date Title
IL214822A0 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
PT2482812T (pt) Composições farmacêuticas compreendendo bi-1356 e metformina
IL214425A (en) Converted metastatic heterocyclic compounds, their pharmaceutical preparations and their uses
EP2254555A4 (en) APREPITANT FORMS WITH INCREASED SOLUBILITY AND PHARMACEUTICAL COMPOSITIONS FROM THEREOF
EP2395975A4 (en) ORAL PHARMACEUTICAL COMPOSITION OF DUTASTERIDE
ZA201108292B (en) New compounds,pharmaceutical composition and methods relating thereto
PL2281822T3 (pl) Nowe pochodne dihydroindolonów, sposób ich wytwarzania i zawierające je kompozycje farmaceutyczne
ZA200903858B (en) Pharmaceutical dosage form
ZA201107104B (en) Derivatives of benzothiazines,preparation thereof and application thereof as drugs
PL2504331T3 (pl) Związek, jego nowe formy, zawierające je kompozycje farmaceutyczne i sposoby otrzymywania oraz zastosowanie
IL248077B (en) Formulations, salts and polymers of transnorsertraline and their uses
IL216462A (en) Pharmaceuticals containing nitrile history and uses
IL213177A0 (en) Crystal forms, methods of preparation, pharmaceutical compositions and uses of nicousamide
ZA201303692B (en) Diphenyl-amine derivatives:uses,process of synthesis and pharmaceutical compositions
IL211062A0 (en) Pharmaceutical uses of lanosta-8,24-dien-3-ols
GB201210536D0 (en) Composition, use and method of preparation thereof
PL2484661T3 (pl) Pochodna 2,3-dihydro-1h-inden-2-ylomocznika i jej zastosowanie farmaceutyczne
EP2496568A4 (en) POLYMORPH OF 3- (SUBSTITUTED DIHYDROISOINDOLINONE-2-YL) -2,6-DIOXOPIPERIDINE AND PHARMACEUTICAL COMPOSITION THEREOF
GB0902648D0 (en) Pharmaceutical compounds and compositions
IL219018A (en) Radzolid Pharmaceuticals and Uses
EP2626347A4 (en) DALFAMPRIDINPOLYMORPH AND THE PREPARATION AND USE THEREOF
ZA201105443B (en) Novel saponin compounds,methods of preparation thereof,use thereof and pharmaceutical compositions
EP2404588A4 (en) PACKAGING FOR SOLID PHARMACEUTICAL PREPARATION
PL2277511T3 (pl) Kompozycje farmaceutyczne lewetiracetamu o przedłużonym uwalnianiu
GB0908317D0 (en) Pharmaceutical compounds and compositions